ReviewEuropean respiratory review : an official journal of the European Respiratory Society2019
The genetics of interstitial lung diseases.
Review in European respiratory review : an official journal of the European Respiratory Society, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 2 syntheses or guidelines pooled it, 59 citations in OpenAlex.
- Interstitial lung disease epidemiology and etiology in patients with solid malignant tumors: a systematic literature review.Future oncology (London, England) · 2025Pooled it
- The disease burden of ILD at the global, regional, and national levels from 1990 to 2021, and projections until 2035: the 2021 Global Burden of Disease study.Frontiers in medicine · 2025Pooled it
- Geographical, institutional and workplace variability in genetic evaluation, screening practices, multidisciplinary care, and lung transplantation management for familial interstitial lung disease.BMC pulmonary medicine · 2026Article
- The Genetic Landscape of Fibrotic Interstitial Lung Diseases: Clinical Implications and Diagnostic Challenges in Familial Pulmonary Fibrosis.Journal of clinical medicine · 2026Review
- Interstitial lung disease and the STING pathway.The Journal of clinical investigation · 2026Review
- Molecular Investigation in Early-Onset Interstitial Lung Disease: Results From 699 Unrelated Patients.Respirology (Carlton, Vic.) · 2026Article
- Antifibrotic therapy in familial idiopathic pulmonary fibrosis: a comparative cohort study.Scientific reports · 2025Article
- The global burden of heart failure attributable to interstitial lung diseases: insights from the global burden of disease study 2021.BMC cardiovascular disorders · 2025Article
- Identification of early genes in the pathophysiology of fibrotic interstitial lung disease in a new model of pulmonary fibrosis.Cellular and molecular life sciences : CMLS · 2025Article
- Advances in Extracellular Matrix-Associated Diagnostics and Therapeutics.Journal of clinical medicine · 2025Review
- Diagnosis, screening, and follow-up of patients with familial interstitial lung disease: Results from an international survey.BMC pulmonary medicine · 2025Article
- Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease.Life (Basel, Switzerland) · 2024Review
- The Coronavirus Disease 2019 Pandemic and Time to Diagnosis for Childhood Pulmonary Diseases: Outcomes of a Tertiary Care Center.Turkish archives of pediatrics · 2024Article
- Current Landscape and Future Directions of Patient Education in Adults with Interstitial Lung Disease.ATS scholar · 2024Review
- A novel mutation of CTC1 leads to telomere shortening in a chinese family with interstitial lung disease.Hereditas · 2023Article
- No effect of danazol treatment in patients with advanced idiopathic pulmonary fibrosis.ERJ open research · 2023Article
- Proprotein Convertase Subtilisin/Kexin Type 6: A Risk Factor for Survival in Pulmonary Fibrosis?American journal of respiratory and critical care medicine · 2023Article
- Use of Next-Generation Sequencing to Support the Diagnosis of Familial Interstitial Pneumonia.Genes · 2023Article
- Present and future perspectives in early diagnosis and monitoring for progressive fibrosing interstitial lung diseases.Frontiers in medicine · 2023Article
- Novel diagnostic techniques in interstitial lung disease.Frontiers in medicine · 2023Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Interstitial lung diseases (ILDs) are a set of heterogeneous lung diseases characterised by inflammation and, in some cases, fibrosis. These lung conditions lead to dyspnoea, cough, abnormalities in gas exchange, restrictive physiology (characterised by decreased lung volumes), hypoxaemia and, if progressive, respiratory failure. In some cases, ILDs can be caused by systemic diseases or environmental exposures. The ability to treat or cure these ILDs varies based on the subtype and in many cases lung transplantation remains the only curative therapy. There is a growing body of evidence that both common and rare genetic variants contribute to the development and clinical manifestation of many of the ILDs. Here, we review the current understanding of genetic risk and ILD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.